Possibilities of improving the parameters of hyperthermia in regional isolated limb perfusion using epidural bupivacaine and accurate temperature measurement of the three layers of limb tissue

Melanoma Research

Volumn 16, Issue 3, 2006, Pages 249-257

  Jastrzȩbski, Tomasz ^a   Sommer, Anna ^a   Świerblewski, Maciej ^a   Lass, Piotr ^b   Rogowski, Jan ^a   Drucis, Kamil ^a   Kopacz, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Hyperthermic; Melanoma; Perfusion

Indexed keywords

BUPIVACAINE; CYTOSTATIC AGENT; HEPARIN; MELPHALAN; TECHNETIUM 99M;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEATING; HUMAN; HYPERTHERMIC THERAPY; LEG MUSCLE; LIMB PERFUSION; LOW TEMPERATURE PROCEDURES; MALE; MELANOMA; MENINX; METASTASIS; PRIORITY JOURNAL; SKIN TEMPERATURE; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS TISSUE; TEMPERATURE MEASUREMENT; THIGH;

ADULT; AGED; BUPIVACAINE; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, EPIDURAL; LOWER EXTREMITY; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PERFUSION;

EID: 33746165141     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000205018.15988.ed     Document Type: Article

References (26)

1. White R, Stanley W, Johnson J, Tyler D, Seigler H. Long-term survival in 2505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002; 235:879-887.
2. Creech O, Ryan R, Krementz E. Treatment of malignant melanoma by isolation perfusion technique. JAMA 1959; 169:339.
3. Stehlin J, Clark R, White E. Regional chemotherapy for cancer: experiences with 116 perfusion. Ann Surg 1960; 151:605.
4. Cavaliere R, Ciocatto E, Giovanella B. Selective heat sensitivity of cancer cells. Biochemical and clinical study. Cancer 1967; 20:1351-1381.
5. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997; 79:1129-1137.
6. ESMO. Minimum clinical recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma. Ann Oncol 2005; 16 (Suppl 1):i66-i68.
7. Kroon B. Regional isolation perfusion in melanoma of the limbs; accomplishment, unsolved problems, future. Eur J Surg Oncol 1988; 14:101-110.
8. Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune F. High-dose recombinant tumor necrosis factor alpha in combination with interferon-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
9. Lejeune F, Lienard D, Leyvraz S, Mirimanoff R. Regional therapy of melanoma. Eur J Cancer 1993; 29:606-612.
10. Eggermont A. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996; 26:335-349.
11. Fraker D, Alexander H, Andric M, Rosenberg S. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995; 1:122.
12. Eggermont A, de Wilt J, ten Hagen T. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4:429-437.
13. Eggermont A, Schrafford Koops H, Klausner J, Kroon B, Schlag P, Lienard J, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 1996; 224:756-765.
14. Lienard D, Eggermont A, Koops S, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9:491-502.
15. de Wilt J, Hagen T, de Boeck G, van Tiel S, Eggermont A. Tumour necrosis factor alpha increases melphalan concentration in tumor tissue after isolated limb perfusion. Br J Cancer 2000; 82:1000-1003.
16. Thompson J, Siebert G, Anissimov Y, Smithers B, Doubrovsky A, Anderson C, Roberts M. Microdialysis and response during regional chemotherapy by isolated infusion of melphalan for limb malignances. Br J Cancer 2001; 85:157-165.
17. Krementz E, Carter D, Sutherland C, Campbell M. The use of regional chemotherapy in the management of malignant melanoma. World J Surg 1979; 3:289-304.
18. Papa M, Klein E, Karni T, Kollr M, Davidson B, Aziz E, Ben-Ari G. Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities. Am J Surg 1996; 171:416-420.
19. Vrouenraets B, Kroon B, Klaase J, Nieweg O, van Slooten G, van Dongen J. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995; 5:425-431.
20. Daryanani D, Komdeur R, Ter Veen J, Nijhuis P, Piers D, Hoekstra H. Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 2001; 8:566-572.
21. Vaglini M, Santinami M, Nava M, Belli F, Prada A, Ammatuna M, Cascinelli N. Hyperthermic antiblastic perfusion in extracorporeal circulation: surgical technique and results in the treatment of extremities' tumor. J Extra-Corporeal Techn 1986; 18:12-20.
22. Ghusen F, Kruger I, Smalley R, Groth W. Hyperthermic perfusion with chemotherapy for melanoma of the extremities. World J Surg 1989; 13:598-602.
23. Skene A, Bulman A, Williams T, Thomas J, Westbury G. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990; 77:765-767.
24. Hohenberger P, Finke L, Schlag P. Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma. Eur J Surg Oncol 1996; 22:147-151.
25. Koops S, Vaglini M, Suciu S, Kroon B, Thompson J, Gohl J, et al., on behalf EORTC Malignant Melanoma Cooperative Group. Protocol 18832, the WHO Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16:2906-2912.
26. Rossi C, Foletto M, Mocellin S, Pilati P, Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004; 11:173-177.